Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet’s disease

Kim, H. J.; Kim, K.‐t.; Lee, S.-G.; Kim, Y.

doi:10.1007/s00393-020-00816-0

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further analysis showed that the three drugs were in the metabolic pathway of arachidonic acid, which was very important for inflammation effects. − The drug 5-aminosalicylic acid (5-ASA) is the first-line therapy for treating patients with mild-to-moderate ulcerative colitis, could inhibit the synthesis of prostaglandins and the formation of the inflammatory mediator leukotrienes . Additionally, 5-ASA is commonly used in many drug combination regimens for the treatment of enterocolitis. , …”

Section: Resultsmentioning

confidence: 99%

“…52 Additionally, 5-ASA is commonly used in many drug combination regimens for the treatment of enterocolitis. 53,54 Based on these findings, we administered compound 33 and 5-ASA simultaneously to test their combination therapeutic effect on IBD. As shown in Figure 5C−H, the combination treatment showed better therapeutic effects than the administration of compound 33 alone, some of these effects included lower body weight loss (Figure 5C), better DAI score (Figure 5D), longer colon length (Figure 5E), and a lower spleen index (Figure 5F).…”

Section: ■ Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease

Li,

Xu,

Zhao

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a multifactorial chronic inflammation of the intestine and has become a global public health concern. A farnesoid X receptor (FXR) was recently reported to play a key role in hepatic-intestinal circulation, intestinal metabolism, immunity, and microbial regulation, and thus, it becomes a promising therapeutic target for IBD. In this study, we identified a series of nonbile acid FXR agonists, in which 33 novel compounds were designed and synthesized by the structure-based drug design strategy from our previously identified hit compound. Compound 33 exhibited a potent FXR agonistic activity, high intestinal distribution, good anti-inflammatory activity, and the ability to repair the colon epithelium in a DSS-induced acute enteritis model. Based on the results of RNA-seq analysis, we further investigated the therapeutic potential of the combination of compound 33 with 5-ASA. Overall, the results indicated that compound 33 is a promising drug candidate for IBD treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: ■ Introductionmentioning

confidence: 99%

Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease

Li,

Xu,

Zhao

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“…Subsequently, the FDA‐approved indications have been expanded to ankylosing spondylitis, IBD (CD and ulcerative colitis), plaque psoriasis, hidradenitis suppurativa, and uveitis 15 . Currently, ADA is used in rheumatology, gastroenterology, and dermatology 16 …”

Section: Main Types Of Biologics Used To Treat Rras and Their Mechani...mentioning

confidence: 99%

Role of biologics in refractory recurrent aphthous stomatitis

Liu

Zhang

Zhou

et al. 2022

J Oral Pathology Medicine

View full text Add to dashboard Cite

Refractory recurrent aphthous stomatitis (RRAS) manifests as severe ulcerative lesions of the oral mucosa with poor healing and a poor response to conventional therapy, with or without systemic diseases. Its treatment remains a clinical challenge owing to the lack of effective therapies. Recently, biologics have emerged as promising targeted therapies for RRAS. The biologics targeting specific inflammatory pathways involved in the pathogenesis of RRAS, including tumor necrosis factor-alpha inhibitors and interleukin inhibitors, offer a more precise and promising therapeutic approach for RRAS. These targeted therapies have been shown to promote healing and decrease recurrence frequency in, and improve the quality of life of patients with RRAS. Herein, the types and mechanisms of biologics currently used to treat RRAS have been reviewed; furthermore, the dose, duration, therapeutic efficacy, and adverse effects of RRAS with or without certain associated systemic diseases, and the current problems and future directions have been discussed.

show abstract

A Contemporary Review of Behcet’s Syndrome

Chen

2021

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet’s disease

Cited by 4 publications

References 11 publications

Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease

Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease

Role of biologics in refractory recurrent aphthous stomatitis

A Contemporary Review of Behcet’s Syndrome

Contact Info

Product

Resources

About